![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immunodiagnostic Systems Holdings Plc | LSE:IDH | London | Ordinary Share | GB00B01YZ052 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 378.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMIDH
RNS Number : 6177Z
Immunodiagnostic Systems Hldgs PLC
24 May 2021
FORM 8 (OPD)
PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER
Rules 8.1 and 8.2 of the Takeover Code (the "Code")
1. KEY INFORMATION (a) Full name of discloser: Immunodiagnostic Systems Holdings plc (b) Owner or controller of interests and short positions disclosed, if N/A different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. -------------------------------------- (c) Name of offeror/offeree in relation to whose relevant securities this Immunodiagnostic Systems Holdings plc form relates: Use a separate form for each offeror/offeree -------------------------------------- (d) Is the discloser the offeror or the offeree? OFFEREE -------------------------------------- (e) Date position held: 21 May 2021 The latest practicable date prior to the disclosure -------------------------------------- (f) In addition to the company in 1(c) above, is the discloser making N/A disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state "N/A" -------------------------------------- 2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates
Class of relevant security: Interests Short positions ------------- ------------------ Number % Number % --------- ------------- --- (1) Relevant securities owned and/or controlled: NIL 0 NIL 0 --------- ------------- --- (2) Cash-settled derivatives: NIL 0 NIL 0 --------- ------------- --- (3) Stock-settled derivatives (including options) and agreements to purchase/sell: NIL 0 NIL 0 --------- ------------- --- TOTAL: NIL 0 NIL 0 --------- ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
(b) Rights to subscribe for new securities Class of relevant security in relation to which subscription right exists: N/A Details, including nature of the rights concerned and relevant percentages: N/A ---- 3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure: a) Interests of directors of Immunodiagnostic Systems Holdings plc in Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each Name Number of ordinary Percentage of total shares of 2 pence issued share capital each (%) (excluding treasury shares and any shares held under option) --------------------- ----------------------- Klaus Peter Kaspar 18,100 0.06 --------------------- ----------------------- Paul James Martin 22,350 0.08 --------------------- ----------------------- Jaap Stuut 7,500 0.03 --------------------- ----------------------- Peter John Williamson 45,000 0.16 --------------------- ----------------------- Burkhard Wittek* 8,259,759 28.70 --------------------- ----------------------- *Dr Wittek's shares are held by Forum Venture Capital GmbH, Forum European Smallcaps GmbH, Forum Family Office Venture Fund and his spouse and children b) Details of awards granted to the directors of Immunodiagnostic Systems Holdings plc over Immunodiagnostic Systems Holdings plc's ordinary shares of 2 pence each Name Number Percentage Grant Vesting Exercise Expiry of ordinary of total date date price date shares issued share (p) of 2 capital (%) pence (excluding each any shares held under option) -------------- ------------- --------- -------- --------- --------- Jaap Stuut 7,500 0.03 29/03/18 29/03/21 220 29/03/28 -------------- ------------- --------- -------- --------- --------- Jaap Stuut 7,500 0.03 28/03/19 06/12/21 190 28/03/29 -------------- ------------- --------- -------- --------- --------- Jaap Stuut 7,500 0.03 31/03/20 20/02/23 210 31/03/30 -------------- ------------- --------- -------- --------- --------- Jaap Stuut 7,500 0.03 17/05/21 29/03/24 195 17/05/31 -------------- ------------- --------- -------- --------- --------- Paul Martin 30,000 0.10 28/03/17 23/06/19 132 28/03/27 -------------- ------------- --------- -------- --------- --------- Paul Martin 9,000 0.03 28/03/17 28/03/20 277.5 28/03/27 -------------- ------------- --------- -------- --------- --------- Paul Martin 6,300 0.02 29/03/18 20/06/20 290 29/03/28 -------------- ------------- --------- -------- --------- --------- Paul Martin 2,283 0.01 29/03/18 29/03/21 220 29/03/28 -------------- ------------- --------- -------- --------- --------- Paul Martin 3,717 0.01 29/03/18 29/03/21 220 29/03/28 -------------- ------------- --------- -------- --------- --------- Paul Martin 6,750 0.02 28/03/19 06/12/21 184 28/03/29 -------------- ------------- --------- -------- --------- --------- Paul Martin 30,000 0.10 25/06/19 23/06/22 180 25/06/29 -------------- ------------- --------- -------- --------- --------- Paul Martin 9,000 0.03 31/03/20 21/02/23 220 31/03/30 -------------- ------------- --------- -------- --------- --------- Paul Martin 9,000 0.03 31/03/20 23/03/23 170 31/03/30 -------------- ------------- --------- -------- --------- --------- Paul Martin 6,300 0.02 17/05/21 20/06/23 275 17/05/31 -------------- ------------- --------- -------- --------- --------- Paul Martin 6,000 0.02 17/05/21 29/03/24 195 17/05/31 -------------- ------------- --------- -------- --------- ---------
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).
4. OTHER INFORMATION (a) Indemnity and other dealing arrangements Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none" None (b) Agreements, arrangements or understandings relating to options or derivatives Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state "none" None (c) Attachments
Are any Supplemental Forms attached?
Supplemental Form 8 (Open Positions) NO Supplemental Form 8 (SBL) NO --- Date of disclosure: 24 May 2021 Contact name: Paul Martin ---------------------- Telephone number: +44 ( 0) 191 519 6111 ----------------------
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.
The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
FEEEAASLADXFEFA
(END) Dow Jones Newswires
May 24, 2021 08:39 ET (12:39 GMT)
1 Year Immunodiagnostic Systems Chart |
1 Month Immunodiagnostic Systems Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions